Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic
Concept/Terms
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Compounds, 3-Ring Heterocyclic
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in Harvard Catalyst Profiles by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 3 | 4 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 4 | 8 |
| 2018 | 12 | 3 | 15 |
| 2019 | 7 | 6 | 13 |
| 2020 | 8 | 2 | 10 |
| 2021 | 5 | 9 | 14 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 6 | 6 |
| 2024 | 1 | 3 | 4 |
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Viruses. 2024 Mar 04; 16(3).
-
Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children. J Acquir Immune Defic Syndr. 2024 03 01; 95(3):297-303.
-
A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib. J Drugs Dermatol. 2024 Feb 01; 23(2):e60-e63.
-
Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Expert Rev Clin Immunol. 2024 02; 20(2):141-153.
-
Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2024 Mar; 22(3):666-668.
-
Metabolic implications and safety of dolutegravir use in pregnancy. Lancet HIV. 2023 09; 10(9):e606-e616.
-
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. J Antimicrob Chemother. 2023 08 02; 78(8):2000-2007.
-
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Upadacitinib as a Novel Treatment in Therapy Refractory Collagenous Colitis. Inflamm Bowel Dis. 2023 08 01; 29(8):1352-1353.
-
Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis. 2023 07 05; 29(7):1175-1176.